Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level

被引：3
|
作者：
Bazhenova, L. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 04期
关键词：
1ST-LINE NIVOLUMAB; PLUS IPILIMUMAB; ADENOCARCINOMA; CHEMOTHERAPY; SENSITIVITY; ASSOCIATION; EFFICACY; OUTCOMES; NSCLC;
D O I：
10.1016/j.annonc.2023.02.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] A comparative meta-analysis of survival outcomes in Non-Small Cell Lung Cancer: Influence of tumor mutational burden and KEAP1, KRAS, STK11 mutations on the efficacy of immunotherapy combined with chemotherapy versus chemotherapy alone
    Elfaituri, Muhammed Khaled
    Khaled, Ala
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [32] STK11/LKB1 mutation in non-small cell lung cancer: Prognostic or predictive?
    Rosellini, P.
    Girodet, P. O.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 50 - 51
  • [33] Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma
    Liang, Yao
    Maeda, Osamu
    Kondo, Chiaki
    Nishida, Kazuki
    Ando, Yuichi
    PLOS ONE, 2024, 19 (07):
  • [34] Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
    Domingues, I.
    Cedres, S.
    Callejo, A.
    Vivancos, A.
    Martinez-Marti, A.
    Felip, E.
    PULMONOLOGY, 2020, 26 (01): : 49 - 50
  • [35] Analysis of survival outcomes in patients with non-small-cell lung cancer with mutations in STK11/LKB1 receiving chemoimmunotherapy.
    Kim, Diana
    Elsey, Rachel
    Meissner, Tobias
    Sun, Yuliang
    Xu, Bing
    Hattum, Crystal
    Solomon, Benjamin Maurice
    Lee, John H.
    Williams, Casey B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Retrospective Evaluation of Biomarkers (KRAS, TP53, STK11, KEAP1, POLE, PIK3CA, ARID1A) In Patients with NSCLC IV
    Roeper, J.
    Falk, M.
    Schatz, S.
    Heukamp, L.
    Griesinger, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S613 - S614
  • [37] Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer
    Principe, Daniel R.
    Pasquinelli, Mary M.
    Nguyen, Ryan H.
    Munshi, Hidayatullah G.
    Hulbert, Alicia
    Aissa, Alexandre F.
    Weinberg, Frank
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 2282 - 2294
  • [38] Mutations of the LKB1/STK11 gene in non-small cell lung cancer with loss of heterozygosity
    Yang, Sei-Hoon
    Meerzaman, Daoud
    Mechanic, Leah E.
    Gill, Rajbir
    Dracheva, Tatiana
    Han, Seung-Bum
    Kim, Sam-Yong
    Bowman, Elise D.
    Harris, Curtis C.
    Jen, Jin
    ANNALS OF ONCOLOGY, 2006, 17 : 246 - 246
  • [39] Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
    R K Gill
    S-H Yang
    D Meerzaman
    L E Mechanic
    E D Bowman
    H-S Jeon
    S Roy Chowdhuri
    A Shakoori
    T Dracheva
    K-M Hong
    J Fukuoka
    J-H Zhang
    C C Harris
    J Jen
    Oncogene, 2011, 30 : 3784 - 3791
  • [40] Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
    Gill, R. K.
    Yang, S-H
    Meerzaman, D.
    Mechanic, L. E.
    Bowman, E. D.
    Jeon, H-S
    Chowdhuri, S. Roy
    Shakoori, A.
    Dracheva, T.
    Hong, K-M
    Fukuoka, J.
    Zhang, J-H
    Harris, C. C.
    Jen, J.
    ONCOGENE, 2011, 30 (35) : 3784 - 3791
12345